TriangleGemtuzumab Ozogamicin (NCT03737955)
Gemtuzumab Ozogamicin trial for Acute Myeloid Leukemia (NCT03737955). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with CD33-positive acute myeloid leukemia who have measurable residual disease after induction chemotherapy but meet remission criteria. Acute promyelocytic and biphenotypic leukemia are excluded.
The idea: gemtuzumab ozogamicin attaches to CD33 and delivers a chemotherapy payload. Infusions occur on days one, four, and seven. A second course may be offered without significant first-course side effects. Researchers use marrow and blood samples to assess residual-disease clearance and compare responses by CD33 genotype.
This phase 2 study plans 36 patients. Mary-Elizabeth Percival leads in Seattle, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.